|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith JS, Lindsay L, Hoots B, et al: Human
papillomavirus type distribution in invasive cervical cancer and
high-grade cervical lesions: a meta-analysis update. Int J Cancer.
121:621–632. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiffman M, Castle PE, Jeronimo J,
Rodriguez AC and Wacholder S: Human papillomavirus and cervical
cancer. Lancet. 370:890–907. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bosch FX, Manos MM, Muñoz N, et al:
Prevalence of human papillomavirus in cervical cancer: a worldwide
perspective. International biological study on cervical cancer
(IBSCC) Study Group. J Natl Cancer Inst. 87:796–802. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Walboomers JM, Jacobs MV, Manos MM, et al:
Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DeFilippis RA, Goodwin EC, Wu L and DiMaio
D: Endogenous human papillomavirus E6 and E7 proteins
differentially regulate proliferation, senescence, and apoptosis in
HeLa cervical carcinoma cells. J Virol. 77:1551–1563. 2003.
View Article : Google Scholar :
|
|
7
|
Accardi L, Paolini F, Mandarino A, et al:
In vivo antitumor effect of an intracellular single-chain antibody
fragment against the E7 oncoprotein of human papillomavirus 16. Int
J Cancer. 134:2742–2747. 2014. View Article : Google Scholar
|
|
8
|
Govan VA: Strategies for human
papillomavirus therapeutic vaccines and other therapies based on
the E6 and E7 oncogenes. Ann N Y Acad Sci. 1056:328–343. 2005.
View Article : Google Scholar
|
|
9
|
Ressing ME, Sette A, Brandt RM, et al:
Human CTL epitopes encoded by human papillomavirus type 16 E6 and
E7 identified through in vivo and in vitro immunogenicity studies
of HLA-A*0201-binding peptides. J Immunol. 154:5934–5943.
1995.PubMed/NCBI
|
|
10
|
Zwaveling S, Ferreira Mota SC, Nouta J, et
al: Established human papillomavirus type 16-expressing tumors are
effectively eradicated following vaccination with long peptides. J
Immunol. 169:350–358. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qian X, Lu Y, Liu Q, et al: Prophylactic,
therapeutic and anti-metastatic effects of an
HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal
model. Immunol Lett. 102:191–201. 2006. View Article : Google Scholar
|
|
12
|
Liu B, Ye D, Song X, et al: A novel
therapeutic fusion protein vaccine by two different families of
heat shock proteins linked with HPV16 E7 generates potent antitumor
immunity and antiangiogenesis. Vaccine. 26:1387–1396. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou CM, Zhang GX and Ma XX:
Characterization and evaluation of the immune responses elicited by
a novel human papillomavirus (HPV) therapeutic vaccine: HPV
16E7-HBcAg-Hsp65 fusion protein. J Virol Methods. 197:1–6. 2014.
View Article : Google Scholar
|
|
14
|
Zong J, Wang C, Liu B, et al: Human hsp70
and HPV16 oE7 fusion protein vaccine induces an effective antitumor
efficacy. Oncol Rep. 30:407–412. 2013.PubMed/NCBI
|
|
15
|
Li YL, Qiu XH, Shen C, Liu JN and Zhang J:
Vaccination of full-length HPV16 E6 or E7 protein inhibits the
growth of HPV16 associated tumors. Oncol Rep. 24:1323–1329.
2010.PubMed/NCBI
|
|
16
|
Li YL, Liu J, Liu JN and Zhang J:
Immunization of protein HPV16 E7 in fusion with mouse HSP70
inhibits the growth of TC-1 cells in tumor bearing mice. Vaccine.
29:5959–5962. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dalal S, Gao Q, Androphy EJ and Band V:
Mutational analysis of human papillomavirus type 16 E6 demonstrates
that p53 degradation is necessary for immortalization of mammary
epithelial cells. J Virol. 70:683–688. 1996.PubMed/NCBI
|
|
18
|
Edmonds C and Vousden KH: A point
mutational analysis of human papillomavirus type 16 E7 protein. J
Virol. 63:2650–2656. 1989.PubMed/NCBI
|
|
19
|
Watanabe S, Kanda T, Sato H, Furuno A and
Yoshiike K: Mutational analysis of human papillomavirus type 16 E7
functions. J Virol. 64:207–214. 1990.PubMed/NCBI
|
|
20
|
Mahdavi A and Monk BJ: Vaccines against
human papillomavirus and cervical cancer: promises and challenges.
Oncologist. 10:528–538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji H, Chang EY, Lin KY, et al:
Antigen-specific immunotherapy for murine lung metastatic tumors
expressing human papillomavirus type 16 E7 oncoprotein. Int J
Cancer. 78:41–45. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun Z, Lu W, Tang Y, et al: Expression,
purification and characterization of human urodilatin in E. coli.
Protein Expr Purif. 55:312–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang WH ZJ, Wang ZY and Hong MM: SDS-PAGE
determination of HIS-TAG fusion protein molecular weight of the
reasons for bias. J Plant Physiol Mol Biol. 26:64–68. 2000.
|
|
25
|
Tamura Y, Peng P, Liu K, Daou M and
Srivastava PK: Immunotherapy of tumors with autologous
tumor-derived heat shock protein preparations. Science.
278:117–120. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang XY, Kazim L, Repasky EA and Subjeck
JR: Characterization of heat shock protein 110 and
glucose-regulated protein 170 as cancer vaccines and the effect of
fever-range hyperthermia on vaccine activity. J Immunol.
166:490–497. 2001. View Article : Google Scholar
|
